Underpowered trials at trial start and informed consent: action is needed beyond the COVID-19 pandemic

Emanuel EJ Wendler D Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701–2711

Halpern SD Karlawish JHT Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288: 358–362.

Honarmand K Penn J Agarwal A Siemieniuk R Brignardello-Petersen R Bartoszko JJ , et al. Clinical trials in COVID-19 management & prevention: a meta-epidemiological study examining methodological quality. J Clin Epidemiol 2021; 139: 68–79

Bugin K Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov 2021: 20: 254–255.

Faust A Sierawska A Krüger K Wisgalla A Hasford J Strech D. Challenges and proposed solutions in making clinical research on COVID-19 ethical: a status quo analysis across German research ethics committees. BMC Med Ethics 2021; 22: 96.

Naci H Kesselheim AS Røttingen JA Salanti G Vandvik PO Cipriani A. Producing and using timely comparative evidence on drugs: lessons from clinical trials for Covid-19. BMJ 2020; 371: m3869.

Petkova E Antman EM Troxel AB. Pooling data from individual clinical trials in the COVID-19 era. JAMA 2020; 324: 543–545.

Lee SM Esserman D Cheung K Dziura J Peduzzi P Sobieszczyk M. What do we do with our under-enrolled single-center COVID-19 clinical trials? Clin Trials 2021; 18: 741–742.

Janiaud P Axfors C Schmitt AM Gloy V Ebrahimi F Hepprich M , et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA 2021; 325: 1185–1195.

Dal-Ré R Voo TC Holm S. Adaptive, platform trials assessing therapies for hospitalized COVID-19 patients: informed consent forms omitted a few important elements of information. J Glob Health 2023; 13: 06019.

Ehrmann S Li J Ibarra-Estrada M Perez Y Pavlov I McNicholas B , et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Resp Med 2021, 9: 1387–1395.

Reynolds KA Harikumar VB Poon E West DP Alam M. While ethical considerations predominate, scientific merit can impact Institutional Review Board (IRB) determinations: a cross-sectional study. J Clin Epidemiol 2022: 150: 12–17.

Code of Federal Regulations. 45 CFR 46.111 Criteria for IRB approval of research. (a) (1) (i). See www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.111 (last checked 29 May 2024).

European Parliament and the Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 27 May 2014. Off J European Union, L158/1-76. See https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536 (last checked 29 May 2024).

European Medicines Agency. Guideline for Good clinical practice E6(R2). 1 December 2016. EMA/CHMP/ICH/135/1995. See www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf (last checked 29 May 2024).

London AJ Kimmelman J. Against pandemic research exceptionalism. Science 2020; 369: 476–477.